Background: Breast cancer is the major cause of death by cancer among females in developing countries. Although the overall breast cancer incidence rate in the developed countries is double that seen in developing countries (6) and human epidermal growth factor receptor 2 (HER2) (7) status are all major risk factors for relapse. The response of breast cancer patients to hormonal therapy is currently guided by the expression of two steroid hormonal receptors (HR): estrogen receptor-α (ER-α), progesterone receptor (PR) and proliferation marker